Afrigen Biologics & Vaccines plans to start human trials of its Covid-19 vaccine candidate by May, part of a World Health Organization-backed plan to develop locally-made inoculations in the developing world.
Afrigen, which is part of the WHO’s mRNA vaccine technology transfer hub in Cape Town, said in a joint statement the vaccine has shown “a strong immune response” in pre-clinical trials in mice. The vaccine was made by copying the publicly-available sequence of the Moderna Inc. shot provided by Stanford University.
